| Symbol | BIOA |
|---|---|
| Name | BIOAGE LABS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1445A SOUTH,50TH STREET, RICHMOND, California, 94804, United States |
| Telephone | 510-806-1445 |
| Fax | — |
| — | |
| Website | https://www.bioagelabs.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Azelaprag, our lead product candidate, demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function in preclinical obesity models. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. Additional info from NASDAQ: |
GOLDSTEIN DOV A MD 🟡 adjusted position in 0 shares (1 derivative) of BioAge Labs, Inc. (BIOA) at $4.38 Transaction Date: Apr 23, 2026 | Filing ID: 000013
Read moreNew Form ARS - BioAge Labs, Inc. <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0001193125-26-166933 <b>Size:</b> 3 MB
Read moreNew Form DEFA14A - BioAge Labs, Inc. <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0001193125-26-166751 <b>Size:</b> 1 MB
Read moreNew Form DEF 14A - BioAge Labs, Inc. <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0001193125-26-166738 <b>Size:</b> 11 MB
Read moreBioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
Read moreBioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
Read moreRUBIN PAUL D 🟡 adjusted position in 8.8K shares (2 derivative) of BioAge Labs, Inc. (BIOA) at $17.81 Transaction Date: Apr 01, 2026 | Filing ID: 000011
Read more📋 RUBIN PAUL D (Officer) plans to sell 9K shares of BioAge Labs, Inc. (at $17.81 each, total $157K) Filed: Apr 01, 2026 | ID: 002686
Read moreNew Form S-3ASR - BioAge Labs, Inc. <b>Filed:</b> 2026-03-24 <b>AccNo:</b> 0001193125-26-121862 <b>Size:</b> 1 MB
Read moreNew Form S-8 - BioAge Labs, Inc. <b>Filed:</b> 2026-03-24 <b>AccNo:</b> 0001193125-26-121794 <b>Size:</b> 460 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06515418 | Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared wit… | Phase2 | Obesity | Terminated | 2024-06-27 | 2025-02-12 | ClinicalTrials.gov |
| NCT06141889 | Pharmacokinetics Study of Azelaprag (BGE-105) in Older Adult Healthy Volunteers | Phase1 | Healthy Volunteer Study | Completed | 2023-11-17 | 2024-02-02 | ClinicalTrials.gov |
| NCT04815603 | Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Anemia of … | Phase2 | Anemia | Withdrawn | 2021-03-22 | 2022-04-01 | ClinicalTrials.gov |
| NCT04705597 | Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospital… | Phase2 | Covid19 | Terminated | 2021-03-18 | 2022-05-19 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Tirzepatide Placebo | DRUG | Phase PHASE2 | Obesity | TERMINATED | NCT06515418 |
| Tirzepatide | DRUG | Phase PHASE2 | Obesity | TERMINATED | NCT06515418 |
| Oral Placebo for Azelaprag (BGE-105) | DRUG | Phase PHASE2 | Obesity | TERMINATED | NCT06515418 |
| Oral Azelaprag (BGE-105) | DRUG | Phase PHASE2 | Obesity | TERMINATED | NCT06515418 |